WallStreetZenWallStreetZen

NASDAQ: GALT
Galectin Therapeutics Inc Stock Ownership - Who owns Galectin Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Galectin Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jack W. CallicuttChief Financial Officer2025-09-128,706$1.37
$11.93kBuy
Joel LewisPresident and CEO2025-09-1214,000$2.39
$33.46kBuy
Joel LewisPresident and CEO2025-09-1214,000$6.36
$89.05kSell
Jack W. CallicuttChief Financial Officer2025-09-128,706$6.44
$56.06kSell
Kary EldredDirector2025-07-211,000$2.93
$2.93kBuy
Kevin D. FreemanDirector2025-07-175,000$2.90
$14.50kBuy
James C. Czirr10% Owner2025-06-0640,000$1.98
$79.20kBuy
James C. Czirr10% Owner2025-06-0631,250$0.89
$27.81kBuy
James C. Czirr10% Owner2025-06-0646,875$2.39
$112.03kBuy
James C. Czirr10% Owner2025-06-0640,000$2.11
$84.40kBuy

1 of 3

GALT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GALT insiders and whales buy or sell their stock.

GALT Shareholders

What type of owners hold Galectin Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
10x Fund LP35.29%22,604,630$119.80MInsider
James C. Czirr32.81%21,015,907$111.38MInsider
Rod D. Martin18.82%12,057,197$63.90MInsider
Richard E. Uihlein16.12%10,328,981$54.74MInsider
David Platt13.14%8,418,743$44.62MInsider
Vanguard Group Inc3.41%2,184,548$11.58MInstitution
Osaic Holdings Inc1.98%1,265,384$6.71MInstitution
Blackrock Inc1.39%891,879$4.73MInstitution
Joel Lewis1.31%836,592$4.43MInsider
Jane Street Group LLC1.17%748,652$3.97MInstitution

1 of 3

GALT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GALT12.06%87.94%Net BuyingNet Buying
ARCT87.48%12.52%Net BuyingNet Buying
ALDX57.21%27.89%Net SellingNet Selling
JBIO62.49%37.51%Net BuyingNet Buying
DSGN45.90%54.10%Net SellingNet Selling
View Top Biotech Stocks

Galectin Therapeutics Stock Ownership FAQ

Who owns Galectin Therapeutics?

Galectin Therapeutics (NASDAQ: GALT) is owned by 16.33% institutional shareholders, 119.14% Galectin Therapeutics insiders, and 0.00% retail investors. 10x Fund LP is the largest individual Galectin Therapeutics shareholder, owning 22.60M shares representing 35.29% of the company. 10x Fund LP's Galectin Therapeutics shares are currently valued at $110.31M.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.